SCHEMBL25587791

SCHEMBL25587791

CC(C)N(Cc1ccc(Br)c(F)c1)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RIPK1 Q13546 1/20 0.35
PTPRB P23467 1/20 0.34
HTT P42858 1/20 0.32
BMP1 P13497 1/20 0.32
HDAC6 Q9UBN7 4/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC2 Q92769 1/20 0.32
PARP1 P09874 1/20 0.31
MEP1B Q16820 1/20 0.31
APLNR P35414 1/20 0.30
HDAC3 O15379 1/20 0.30
KMT2A Q03164 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
KDM1A O60341 1/20 0.30
RCOR1 Q9UKL0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22651802 0.81 SLC6A2 (0.36) CYP1A2CYP2D6CYP2C9CYP2C19RIPK1
SCHEMBL25587793 0.81 MAOB (0.40) CYP1A2CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL25587767 0.80 CYP1A2 (0.40) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL23961649 0.80 CYP1A2 (0.40) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL22651803 0.77 CNR2 (0.41) CYP1A2CYP2D6CYP2C9CYP2C19RIPK1
SCHEMBL20095413 0.75 HRH3 (0.45) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL13153417 0.75 RIPK1 (0.44) RIPK1TDP1
SCHEMBL25587795 0.75 CYP1A2 (0.49) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL13153418 0.73 RIPK1 (0.49) RIPK1KMT2A
SCHEMBL8252707 0.72 GABRA1 (0.44) CYP1A2CYP2D6CYP2C9CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181592-A1 PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2023-06-15 US disclosed
US-20230181592-A1 PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181592-A1 PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES ADORA1, OXGR1, ADORA2A CYP1A2 1006/4885CYP2D6 824/4885CYP2C9 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.